DrugComb, a one-stop solution to all your cancer drug combination data analysis needs

Assistant Professor Jing Tang, a principal investigator of the Network Pharmacology group at FIMM and at the UH Faculty of Medicine has led the development of DrugComb, an open resource for harmonizing cancer drug combination studies. Dr. Tang hopes that DrugComb would become a collaborative data analysis platform that would bring forth more effective and safer cancer treatments.

2019.06.13 | Annabel Darby

Lab photo

Cancer is a disease that is not only complex, but also wildly heterogeneous. Current cancer treatments are by and large based on “one size fits all” approach, which often results in poor treatment outcomes. While various sources of patient-derived data, such as molecular diagnostics, histopathology and genetic studies provide a glimpse into the inherent complexity of cancer, we still struggle with making informed choices on which therapy would work best for individual patients. That is why poor treatment efficacy, drug resistance or debilitating side effects are unfortunately all too well-known to us. To make cancer more manageable, combining drugs together is believed to be one of the most promising avenues.

Read more:

DrugComb: an integrative cancer drug combination data portal. Bulat Zagidullin, Jehad Aldahdooh, Shuyu Zheng, Wenyu Wang, Yinyin Wang, Joseph Saad, Alina Malyutina, Mohieddin Jafari, Ziaurrehman Tanoli, Alberto Pessia and Jing Tang. Nucleic Acids Research Webserver Issue 2019.

Network pharmacology for precision medicine website

Publication
Tags: Cancer, Personalised medicine